Imunon, Inc.
Close on Oct 19, 2026
- Market cap
- $4.95M
- P/E (TTM)
- –
- Dividend yield
- –
About Imunon
Pharmaceutical Preparations, SIC 2834
Imunon, Inc. is a clinical-stage biotechnology company that creates treatments utilizing non-viral DNA technology to stimulate the human body's natural immunological responses against diseases. The company organizes its technology into two main modalities: TheraPlas, designed to encode proteins and cytokines to treat solid tumors, and PlaCCine, developed for viral antigen coding in infectious disease vaccine initiatives. Its lead clinical immunotherapy candidate, IMNN-001, delivers interleukin-12 locally to treat advanced ovarian cancer. Additionally, the company develops vaccine candidates, including a clinical-stage booster targeting COVID-19.
The company's primary executive offices are located in Lawrenceville, New Jersey. Imunon conducts research, development, and clinical evaluation across domestic sites and facilities, maintaining laboratory and corporate spaces under lease arrangements in Lawrenceville, New Jersey, and Huntsville, Alabama. Its primary target beneficiaries include individuals suffering from advanced cancers and infectious illnesses.
Summary of the business section of Imunon's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Imunon, Inc.
- Headquarters
- Lawrenceville, NJ
- Address
- 997 Lenox Drive, Suite 100 08648
- Phone
- (609) 896-9100
- Website
- imunon.com
- Employees
- 20, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- IMNN
- Exchange
- Nasdaq
- IPO date
- Mar 1, 1999
- Shares outstanding
- 6M, Aug 10, 2026
- Public float
- $21.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Jul 25, 2025; 1-for-15 reverse, Mar 31, 2022; 1-for-15 reverse, Mar 1, 2022; 1-for-25.5 reverse, Aug 14, 2017; 1-for-14 reverse, May 30, 2017; 1-for-4.5 reverse, Oct 28, 2013; 1-for-15 reverse, Feb 28, 2006
- SEC CIK
- 749647
- CUSIP
- 15117N701
- ISIN
- US15117N7012
- LEI
- 529900PWLRCA840VVK89
- EIN
- 52-1256615
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stacy Lindborg | President and CEO, Director | 113,975 |
| Michael H. Tardugno | Executive Chairman of Board, Director | 108,543 |
| Douglas Vincent Faller | Chief Medical Officer | 45,678 |
| Susan Eylward | General Counsel and Corp Sec | 2,896 |
| Joshua Blacher | CFO | – |
| Jeffrey Wayne Church | CFO | 26 |
| Kimberly Bragg | CFO | 20,400 |
| Khursheed Anwer | Chief Scientific Officer | 5,000 |
| Christine A. Pellizzari | Director | 15,076 |
| Frederick J. Fritz | Director | 39,081 |
| James E. Dentzer | Director | 21,897 |
| Donald P. Braun | Director | 15,499 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr.Lindborg | $1.03M | $751.38K | $597.86K | $18 | – |
| FY2024 Dr.Le Goff | $148.87K | -$6.69K | $567.20K | $63 | – |
| FY2024 Dr.Lindborg | $1.19M | $1.13M | $567.20K | $63 | – |
| FY2024 Tardugno | $734.81K | $690.58K | $567.20K | $63 | – |
| FY2023 Dr.Le Goff | $1.06M | $910.53K | $680.04K | $45 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of March 30, 2026, we employed 20 full-time employees.”
Corporate history
Events identified from SEC filings